Brar PC, Heksch R, Cossen K, et al. - Diazoxide, the only FDA-approved pharmacologic treatment for neonatal hypoglycemia caused by hyperinsulinism (HI), has recently been reported to be associated with serious adverse effects (AEs) such as pulmonary hypertension (2-3%) and neutropenia (15%). In view of its increasing use, researchers sought to report on the dosing of diazoxide and/or monitoring for AEs. For this purpose, they performed an extensive literature review and a PES survey revealing a lack of consensus regarding use of diazoxide. Using the framework of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group, researchers graded the evidence and proposed expert consensus practice guidelines for the appropriate use of diazoxide in infants and children with HI. Information on AEs reported to date have been summarized and practical ideas for dosing and monitoring for AEs in infants treated with diazoxide have been given.